Predicting the future of anti-tumor necrosis factor therapy
Division of Inflammatory Disease Profiling, Department of Pathology and Rheumatology, VU University Medical Center, P.O. Box 7057, 1007MB Amsterdam, The Netherlands
Arthritis Research & Therapy 2009, 11:115 doi:10.1186/ar2724
See related research article by Hueber et al., http://arthritis-research.com/content/11/3/R76Published: 22 June 2009
Tumor necrosis factor (TNF) antagonists are approved worldwide for the treatment of rheumatoid arthritis (RA). Clinical experience revealed that TNF-blocking therapy is effective for only approximately two thirds of patients, reflecting that there are 'responders' as well as 'nonresponders'. Given the destructive nature of RA, the risk of adverse effects, and considerable costs for therapy, there is a strong need to make predictions on success before the start of therapy. In the current issue of Arthritis Research & Therapy, Hueber and colleagues become the first to present a multi-parameter serum protein biomarker set that has predictive value prior to the start of anti-TNF treatment. Ultimately, this finding may contribute to a personalized form of medicine, whereby a specific therapy will be applied that is best suited to an individual patient.